PRP vs GFC vs Exosomes – Which Hair Loss Treatment Works Best for Indian Patients?

If you have visited a dermatology clinic or hair restoration centre in the past two years, you have almost certainly been presented with a menu of injectable hair loss treatments: PRP, GFC, and increasingly, exosome therapy. Each is promoted as the next generation of the previous one. Each comes with its own set of claims. And for most patients – sitting across from a doctor they have just met, trying to make a decision about their hair – the differences are genuinely unclear. I see this confusion in my practice every week. Patients from Chandigarh, Ludhiana, Delhi, and even from as far as Jaipur and Lucknow ask me the same question: “Doctor, which one is actually better?” This article is my attempt to answer that question honestly, without overselling any single treatment.

What These Treatments Have in Common – and Where They Differ

PRP, GFC, and exosome therapy all work on the same fundamental principle: delivering biologically active molecules to the scalp that stimulate hair follicle activity, reduce inflammation, and slow the progression of hair loss. Where they differ is in the source of those molecules, their concentration, and the mechanism by which they interact with scalp tissue. Understanding these differences is the key to understanding which treatment is right for a given patient at a given stage of hair loss.

All three are injectable treatments administered in a clinical setting, typically in a series of sessions spaced 4-6 weeks apart. None of them regrow hair where follicles have been completely destroyed – that is the territory of hair transplant surgery. What these treatments do is support and strengthen existing miniaturised follicles, slow progressive loss, improve scalp vascular health, and in many patients, produce measurable increases in hair shaft thickness and density over 6-12 months of consistent treatment.

PRP – Platelet Rich Plasma

PRP is the oldest of the three and the most extensively studied. The treatment involves drawing a small amount of the patient’s own blood (typically 15-30 ml), processing it in a centrifuge to isolate the platelet-rich fraction, and injecting that concentrated plasma into the scalp at follicular level. Platelets release growth factors – primarily PDGF (Platelet-Derived Growth Factor), VEGF (Vascular Endothelial Growth Factor), and IGF-1 (Insulin-like Growth Factor 1) – that stimulate follicle activity and improve blood supply to the hair papilla.

The clinical evidence for PRP is reasonably strong for early-to-moderate androgenetic alopecia (Norwood scale II-IV in men, Ludwig I-II in women). Multiple randomised controlled trials have documented improvements in hair density, shaft diameter, and reduction in hair shedding over 6-12 months of treatment. The standard protocol in most evidence-based clinics is 3-4 sessions over 3 months, followed by maintenance sessions every 4-6 months.

The limitation of PRP is variability. The final concentration of growth factors in a PRP preparation depends heavily on the quality of the centrifuge system, the protocol used, and the baseline platelet count of the individual patient. This means that results between clinics – and even between patients at the same clinic – can vary considerably. A poorly prepared PRP product may be barely above a normal blood draw in terms of growth factor content.

GFC – Growth Factor Concentrate

GFC is the next generation of PRP. It was developed to address PRP’s biggest weakness: variability. Like PRP, GFC is autologous – it is derived from the patient’s own blood. The key difference is in the processing. GFC uses a specific activation protocol to release growth factors directly from the platelets and concentrate them into a small volume of plasma – typically 2-3 ml compared to the 6-8 ml used in standard PRP. The result is a preparation that is consistently 5-10 times more concentrated in active growth factors than conventional PRP.

The clinical outcomes with GFC are generally superior to PRP, with multiple head-to-head comparison studies from Indian dermatology centres showing better hair density outcomes at 6 months compared to standard PRP. The treatment is also slightly more comfortable for patients, as the smaller volume injected into the scalp means fewer injection points and a more targeted delivery. Sessions are typically 3 in number, spaced 4 weeks apart, with maintenance every 4-6 months.

GFC is currently my preferred injectable treatment for moderate hair loss in patients who are not yet candidates for surgery, and as an adjunct for patients who have undergone hair transplant to support the non-transplanted hair. The consistency of the preparation removes much of the variability that plagues conventional PRP protocols.

Exosome Therapy – The Newest Option

Exosome therapy is the most recent entrant and also the most controversial. Exosomes are nano-sized vesicles secreted by stem cells – most commonly from mesenchymal stem cells derived from human umbilical cord tissue or adipose tissue. They carry an extraordinarily rich payload of growth factors, microRNA, and signalling proteins. In theory, a single exosome therapy session delivers a far more potent biological signal to the hair follicle than multiple sessions of GFC or PRP.

The early clinical data from small trials and case series is genuinely impressive. Studies from South Korea, the United States, and a small number of Indian centres have reported significant improvements in hair density, miniaturisation reversal, and patient-reported satisfaction at 6 months that exceed what is typically seen with PRP. The mechanism appears to involve not just growth factor delivery but also epigenetic signalling that influences follicle behaviour at a deeper level than surface-level growth factor stimulation.

However, there are important caveats that patients in India must understand before paying a premium for exosome therapy. First, unlike PRP and GFC, exosome products are not autologous – they come from a donor source, and quality control in the exosome supply chain varies enormously. The regulatory framework for exosome preparations in India is still developing, and not all products available in the market have been independently verified for concentration, sterility, and biological activity. Second, the long-term data is limited. PRP has 15 years of clinical literature. GFC has 7-8 years. Exosomes, in the hair loss application specifically, have 3-4 years of published outcomes at best. The field is moving fast, but caution is warranted.

Side-by-Side Comparison

Who Should Choose Which Treatment?

The practical guidance I give patients in my clinic is as follows. If you are in the early stages of hair loss (Norwood II-III), a course of GFC with concurrent medical management (a topical DHT blocker and, if appropriate, minoxidil) is a well-supported, cost-effective starting point. GFC will deliver measurable improvement for most patients in this category and can be sustained with maintenance sessions at 4-6 month intervals.

If you have had 2-3 courses of PRP at another clinic with minimal response, or if you are dealing with moderate-severe diffuse thinning where hair is thinning across a large area of the scalp, a trial of exosome therapy is a reasonable next step – provided you are accessing it from a reputable clinic that can verify the product quality they are using. Ask specifically about the source of the exosomes, the concentration (measured in units per ml), and the storage conditions. These are not unreasonable questions to ask, and any credible clinic should be able to answer them.

For patients who are surgical candidates – those with stable pattern baldness and adequate donor density – the most rational approach is to combine a hair transplant (using NeoDHT® or NeoPlatinum FUE for the lost zones) with a concurrent GFC protocol for the non-transplanted hair. Surgery gives you permanent, visible density in the areas treated. GFC extends the useful lifespan of the native hair that surgery cannot reach. The combination approach is, in my clinical experience, consistently the most satisfying long-term outcome for patients.

A Note on Cost and Value

Patients frequently ask about the cost of these treatments. I will not give specific figures here because costs vary between clinics, cities, and product quality. What I would say is this: the cheapest version of any of these treatments is almost certainly not the most effective. PRP prepared with a low-grade centrifuge, or exosomes sourced from an unverified supplier, may produce no meaningful benefit at all. The cost of a treatment is only meaningful in the context of what you are actually receiving. If a clinic cannot explain how their PRP is prepared, what centrifuge protocol they use, or where their exosomes are sourced from, that is a significant red flag regardless of the price.

Patients considering any of these treatments are welcome to consult at NeoGraft Hair Clinic in Chandigarh for a full assessment. We see patients from across North India – Punjab, Haryana, Delhi NCR, Himachal Pradesh, Uttarakhand, and further afield. For more information on our approach to hair loss management, visit myneograftindia.com or see our guide on hair transplant for women in India.